D
David Bakish
Researcher at Ottawa Hospital
Publications - 8
Citations - 1231
David Bakish is an academic researcher from Ottawa Hospital. The author has contributed to research in topics: Placebo & Fluoxetine. The author has an hindex of 8, co-authored 8 publications receiving 1191 citations. Previous affiliations of David Bakish include McGill University.
Papers
More filters
Journal ArticleDOI
Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide
Sylvie Lemonde,Gustavo Turecki,David Bakish,Lisheng Du,Pavel D. Hrdina,Christopher D. Bown,Adolfo Sequeira,Neena Kushwaha,Stephen J. Morris,Ajoy Basak,Xiao-Ming Ou,Paul R. Albert +11 more
TL;DR: The data indicate that NUDR is a repressor of the 5-HT1A receptor in raphe cells the function of which is abrogated by a promoter polymorphism, suggesting a novel transcriptional model in which the G(-1019) allele derepresses 5- HT1A autoreceptor expression to reduce serotonergic neurotransmission, predisposing to depression and suicide.
Journal ArticleDOI
Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response.
TL;DR: The results implicate the C(-1019)G 5- HT1A gene polymorphism as a potential marker for antidepressant response, suggesting a role for repression of the 5-HT1A genes.
Journal Article
Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors
TL;DR: The results suggest that upregulation of platelet 5-HT2 receptors is a useful biological marker in major depression, particularly in females.
Journal ArticleDOI
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
Guy Chouinard,Bishan Saxena,Marie-Claire Bélanger,Arun V. Ravindran,David Bakish,Linda Beauclair,Paul Morris,N.P Vasavan Nair,Rahul Manchanda,Robin T. Reesal,Ronald A. Remick,M Colleen O'Neill +11 more
TL;DR: Paroxetine appears to produce an earlier improvement in agitation and psychic anxiety symptoms compared with fluoxetined, and differences observed between the two drugs in antianxiety effects were limited to two measures of anxiety among several others.
Journal Article
A comparison of placebo responders and nonresponders in subgroups of depressive disorder.
TL;DR: The major finding was that patients suffering from their first depressive episode differed from patients with recurrent depressive episodes in the rate of placebo response, effect of gender, and the clinical symptoms that were associated with a positive placebo response.